Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MCL1 as putative target in pancreatoblastoma.
Reissig TM, Uhrig S, Jost PJ, Luchini C, Vicentini C, Liffers ST, Allgäuer M, Adsay V, Scarpa A, Lawlor RT, Fröhling S, Stenzinger A, Klöppel G, Schildhaus HU, Siveke JT. Reissig TM, et al. Among authors: vicentini c. Virchows Arch. 2022 Aug;481(2):265-272. doi: 10.1007/s00428-022-03349-w. Epub 2022 Jun 7. Virchows Arch. 2022. PMID: 35668118 Free PMC article.
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers.
Fassan M, Simbolo M, Bria E, Mafficini A, Pilotto S, Capelli P, Bencivenga M, Pecori S, Luchini C, Neves D, Turri G, Vicentini C, Montagna L, Tomezzoli A, Tortora G, Chilosi M, De Manzoni G, Scarpa A. Fassan M, et al. Among authors: vicentini c. Gastric Cancer. 2014;17(3):442-9. doi: 10.1007/s10120-013-0315-1. Epub 2013 Nov 23. Gastric Cancer. 2014. PMID: 24272205
Evaluation of cell-free DNA as a biomarker for pancreatic malignancies.
Sikora K, Bedin C, Vicentini C, Malpeli G, D'Angelo E, Sperandio N, Lawlor RT, Bassi C, Tortora G, Nitti D, Agostini M, Fassan M, Scarpa A. Sikora K, et al. Among authors: vicentini c. Int J Biol Markers. 2015 Feb 24;30(1):e136-41. doi: 10.5301/jbm.5000088. Int J Biol Markers. 2015. PMID: 24832178 Free article.
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, Melisi D, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A. Simbolo M, et al. Among authors: vicentini c. Oncotarget. 2014 May 15;5(9):2839-52. doi: 10.18632/oncotarget.1943. Oncotarget. 2014. PMID: 24867389 Free PMC article.
Reporting tumor molecular heterogeneity in histopathological diagnosis.
Mafficini A, Amato E, Fassan M, Simbolo M, Antonello D, Vicentini C, Scardoni M, Bersani S, Gottardi M, Rusev B, Malpeli G, Corbo V, Barbi S, Sikora KO, Lawlor RT, Tortora G, Scarpa A. Mafficini A, et al. Among authors: vicentini c. PLoS One. 2014 Aug 15;9(8):e104979. doi: 10.1371/journal.pone.0104979. eCollection 2014. PLoS One. 2014. PMID: 25127237 Free PMC article.
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, Mastracci L, Rusev B, Grillo F, Vicentini C, Ferrara R, Pilotto S, Davini F, Pelosi G, Lawlor RT, Chilosi M, Tortora G, Bria E, Fontanini G, Volante M, Scarpa A. Simbolo M, et al. Among authors: vicentini c. J Pathol. 2017 Mar;241(4):488-500. doi: 10.1002/path.4853. Epub 2016 Dec 29. J Pathol. 2017. PMID: 27873319 Free PMC article.
Fhit down-regulation is an early event in pancreatic carcinogenesis.
Fassan M, Rusev B, Corbo V, Gasparini P, Luchini C, Vicentini C, Mafficini A, Paiella S, Salvia R, Cataldo I, Scarpa A, Huebner K. Fassan M, et al. Among authors: vicentini c. Virchows Arch. 2017 Jun;470(6):647-653. doi: 10.1007/s00428-017-2105-3. Epub 2017 Mar 13. Virchows Arch. 2017. PMID: 28289900 Free PMC article.
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.
Simbolo M, Vicentini C, Ruzzenente A, Brunelli M, Conci S, Fassan M, Mafficini A, Rusev B, Corbo V, Capelli P, Bria E, Pedron S, Turri G, Lawlor RT, Tortora G, Bassi C, Guglielmi A, Scarpa A. Simbolo M, et al. Among authors: vicentini c. Sci Rep. 2018 May 8;8(1):7119. doi: 10.1038/s41598-018-25669-1. Sci Rep. 2018. PMID: 29740198 Free PMC article.
392 results